LTRN: Lantern Pharma Inc. Stocks News on September 3, 2025

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

LTRN

Business Wire

3 months ago

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

LTRN

Simply Wall St.

3 months ago

Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

LTRN

Insider Monkey

3 months ago

Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

LTRN

Business Wire

3 months ago

Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials

LTRN

Zacks Small Cap Research

3 months ago

LTRN: First Quarter 2025 Financial Results

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

LTRN

Business Wire

4 months ago

Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

LTRN

Business Wire

4 months ago

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

LTRN

Benzinga

4 months ago

EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

LTRN

Business Wire

4 months ago

Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET

LTRN

Zacks Small Cap Research

4 months ago

LTRN: IND Clearance for LP-184 in TNBC

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

LTRN

Business Wire

4 months ago

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

LTRN

Benzinga

4 months ago

EXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

LTRN

GuruFocus.com

5 months ago

Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges

LTRN

Zacks Small Cap Research

5 months ago

LTRN: 2024 Financial Results

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

LTRN

Business Wire

5 months ago

Lantern Pharma Provides Business Updates and Fourth Quarter & Year-End 2024 Financial Results

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

LTRN

Business Wire

5 months ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET

How long-term energy plays outshine short-term hype

LTRN

Yahoo Finance Video

6 months ago

How long-term energy plays outshine short-term hype

LTRN

Zacks Small Cap Research

6 months ago

LTRN: M&A Illuminates GBM Value

LTRN

Insider Monkey

6 months ago

Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

LTRN

Business Wire

6 months ago

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

LTRN

Insider Monkey

7 months ago

Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

LTRN

Business Wire

7 months ago

Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer

LTRN

Insider Monkey

8 months ago

Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development

LTRN

Simply Wall St.

8 months ago

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

LTRN

Insider Monkey

9 months ago

AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan

Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial

LTRN

Clinical Trials Arena

9 months ago

Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

LTRN

Business Wire

9 months ago

Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

LTRN

Insider Monkey

9 months ago

Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

LTRN

Business Wire

9 months ago

Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

LTRN

Business Wire

9 months ago

Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

LTRN

Business Wire

9 months ago

Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC™ Clinical Trial of LP-300 in Never-Smoker NSCLC Patients

LTRN

Zacks Small Cap Research

10 months ago

LTRN: Pediatric Rare Cancer in Focus

LTRN

GuruFocus.com

10 months ago

Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

LTRN

Business Wire

10 months ago

Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

LTRN

Business Wire

10 months ago

Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

LTRN

Business Wire

10 months ago

Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

LTRN

Business Wire

10 months ago

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024

Lantern Pharma to Host & Participate in Two Public Webinars During October

LTRN

Business Wire

10 months ago

Lantern Pharma to Host & Participate in Two Public Webinars During October

LTRN

MT Newswires

a year ago

Lantern Pharma's Prospective Brain Tumor Therapy Gets FDA Fast Track Designation

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

LTRN

Business Wire

a year ago

Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA

LTRN

GuruFocus.com

a year ago

Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ...

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers

LTRN

Business Wire

a year ago

Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Children’s Cancers

LTRN

Insider Monkey

a year ago

Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire

LTRN

Zacks Small Cap Research

a year ago

LTRN: Second Quarter Results

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

LTRN

Business Wire

a year ago

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

LTRN

Business Wire

a year ago

Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

LTRN

Zacks Small Cap Research

a year ago

LTRN: Harmonic Clinical Update

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

LTRN

Business Wire

a year ago

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

LTRN

Business Wire

a year ago

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

LTRN

Simply Wall St.

a year ago

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

LTRN

Business Wire

a year ago

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

LTRN

MT Newswires

a year ago

Lantern Pharma Secures Composition of Matter Patent for LP-284 in Japan

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

LTRN

Business Wire

a year ago

Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284

Italian energy company targets Britain for fleet of 20 mini-nukes

LTRN

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

LTRN

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

LTRN

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

LTRN

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

LTRN

Motley Fool

a year ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

LTRN

Simply Wall St.

a year ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

LTRN

Simply Wall St.

a year ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Seoul resumes loudspeaker propaganda against North

LTRN

AFP

a year ago

Seoul resumes loudspeaker propaganda against North

LTRN

MT Newswires

a year ago

Lantern Pharma Files $150 Million Mixed Shelf

LTRN

Zacks Small Cap Research

a year ago

LTRN: Expanding Horizons into Asia

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

LTRN

Business Wire

a year ago

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Lantern Pharma and Oregon partner to develop cancer treatment

LTRN

Pharmaceutical Technology

a year ago

Lantern Pharma and Oregon partner to develop cancer treatment

LTRN

MT Newswires

a year ago

Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

LTRN

Business Wire

a year ago

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

LTRN

Business Wire

a year ago

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

LTRN

Business Wire

a year ago

Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

LTRN

Business Wire

a year ago

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

LTRN

Insider Monkey

a year ago

Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript

LTRN

Zacks Small Cap Research

a year ago

LTRN: 2023 Results

LTRN

GuruFocus.com

a year ago

Lantern Pharma Inc Reports Progress and Financials for FY 2023

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

LTRN

Business Wire

a year ago

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

LTRN

Business Wire

a year ago

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

LTRN

Business Wire

a year ago

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds

LTRN

Insider Monkey

a year ago

11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

LTRN

Business Wire

a year ago

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

LTRN

Business Wire

a year ago

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom

LTRN

InvestorPlace

2 years ago

3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom

LTRN

Zacks Small Cap Research

2 years ago

LTRN: Spotlighting ADCs & Another Orphan

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

LTRN

Business Wire

2 years ago

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

LTRN

Simply Wall St.

2 years ago

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio

LTRN

GlobeNewswire

2 years ago

Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio

LTRN

ACCESSWIRE

2 years ago

Zalatoris Acquisition Corp. Announces Confidential Submission of Draft Registration Statement to the SEC for Proposed Business Combination with AnyTech365

Zentek Announces Eric Wallman Appointed as Chairman of the Board

LTRN

ACCESSWIRE

2 years ago

Zentek Announces Eric Wallman Appointed as Chairman of the Board

D-Wave Quantum to Present at 26th Annual Needham Growth Conference

LTRN

NewMediaWire

2 years ago

D-Wave Quantum to Present at 26th Annual Needham Growth Conference

Blink and McArthurGlen Team Up to Provide EV Chargers at Famous Dutch Designer Outlets

LTRN

GlobeNewswire

2 years ago

Blink and McArthurGlen Team Up to Provide EV Chargers at Famous Dutch Designer Outlets

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

LTRN

Business Wire

2 years ago

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

Sono-Tek Reports 59% Increase in Q3 Fiscal 2024 Net Sales to Record $5.7 Million and Provides Sales Guidance for Fiscal Year 2024

LTRN

GlobeNewswire

2 years ago

Sono-Tek Reports 59% Increase in Q3 Fiscal 2024 Net Sales to Record $5.7 Million and Provides Sales Guidance for Fiscal Year 2024

AxoGen (NASDAQ:AXGN) shareholders have endured a 58% loss from investing in the stock three years ago

LTRN

Simply Wall St.

2 years ago

AxoGen (NASDAQ:AXGN) shareholders have endured a 58% loss from investing in the stock three years ago

D-Wave Becomes First Full-Stack Quantum Provider to Achieve SOC 2 Type 2 Compliance

LTRN

NewMediaWire

2 years ago

D-Wave Becomes First Full-Stack Quantum Provider to Achieve SOC 2 Type 2 Compliance

Rigetti Computing Awarded Innovate UK Grant to Develop Quantum Machine Learning Techniques for Financial Data Streams

LTRN

GlobeNewswire

2 years ago

Rigetti Computing Awarded Innovate UK Grant to Develop Quantum Machine Learning Techniques for Financial Data Streams

Elutia Regains Compliance with Nasdaq Listing Requirements

LTRN

GlobeNewswire

2 years ago

Elutia Regains Compliance with Nasdaq Listing Requirements

SYLA Technologies Appoints Takuya Hanada as Chief Financial Officer

LTRN

GlobeNewswire

2 years ago

SYLA Technologies Appoints Takuya Hanada as Chief Financial Officer

LTRN

Insider Monkey

2 years ago

11 Cheap Pot Stocks to Buy

Chenghe Acquisition I Co. Receives Nasdaq Notice Regarding Late Form 10-Q Filings

LTRN

PR Newswire

2 years ago

Chenghe Acquisition I Co. Receives Nasdaq Notice Regarding Late Form 10-Q Filings

LTRN

GlobeNewswire

2 years ago

FINWARD BANCORP ANNOUNCES FOURTH QUARTER DIVIDEND

Owning 47% shares,institutional owners seem interested in Zalatoris Acquisition Corp. (NYSE:TCOA),

LTRN

Simply Wall St.

2 years ago

Owning 47% shares,institutional owners seem interested in Zalatoris Acquisition Corp. (NYSE:TCOA),

Those who invested in Abeona Therapeutics (NASDAQ:ABEO) a year ago are up 98%

LTRN

Simply Wall St.

2 years ago

Latest Lantern Pharma Inc. (LTRN) News on September 3, 2025

Share on Social Networks: